Subtle. Cumulative. Not a felt nootropic. This is the most "rust-proofing" compound in the entire stack universe — closer in subjective profile to astaxanthin or vitamin E than to anything stimulant- or anxiolytic-class.

• Onset: No acute felt effect. Plasma peaks around 1-3 hours post-dose; tissue accumulation is gradual; clinical-mechanism endpoints (Nrf2 gene induction) measurable in animal models within days but the human subjective experience is essentially nil over weeks-to-months.
• Peak / plateau: After 4-8 weeks of consistent dosing, observable changes (if any) are: marginal improvements in oxidative-stress biomarkers (MDA, oxidized LDL), possibly mild reductions in hsCRP, possibly a slight reduction in post-workout muscle soreness if MMA volume is high. Most users notice nothing subjectively and rely on the mechanism + bloodwork to justify continuation.
• Taper: No withdrawal. Effects fade gradually (weeks) as Nrf2-driven gene-expression changes normalize.
• What it does NOT feel like: Not a stimulant, not a mood-lifter, not a focus enhancer, not a sleep aid. It is fundamentally invisible while it works.

For Dylan specifically: this is firmly in the "insurance compound" category. The marginal subjective benefit at 60-180 mg/day is realistically ~0. The case for adding it is mechanism + cheap + stack-safe, not "this will feel different."

• Tolerance buildup: None reported clinically or anecdotally. Mechanism is gene-induction-based with negative feedback regulation; chronic dosing maintains a steady-state Nrf2-driven expression elevation rather than pushing receptor downregulation.
• Recommended cycle: None required. Daily continuous use is the norm in all preclinical chronic studies (typically 3 months in 5xFAD; longer in metabolic models).
• Reset protocol: Not applicable. If discontinuation is desired, no taper required; effects fade over 2-4 weeks.

Synergistic with

• curcumin (Dylan's V4 Doctor's Best Curcumin Phytosome 500 mg): Strongly synergistic and the cleanest pairing. Both are Nrf2 activators with similar mechanism — curcumin is a direct electrophile via its α,β-unsaturated diketone and a Keap1 cysteine modifier; CA is the proelectrophilic version. They act on overlapping but non-identical Keap1 cysteine sets (Satoh's work suggests partial overlap). Both are anti-inflammatory via NF-κB suppression. Both are fat-soluble. Both BBB-cross. Layered Nrf2 induction with redundant pathways — reduces single-point-of-failure risk in the Nrf2 pathway. Take together at breakfast with fish oil. The Phytosome formulation handles curcumin's bioavailability problem; CA needs the same fat vehicle.
• astaxanthin (Dylan's V5 plan, 12 mg AM): Strongly synergistic. Astaxanthin is a membrane-spanning structural antioxidant (polyene chain quenches peroxyl radicals across the bilayer interior); CA is a mobile lipid-soluble antioxidant + Nrf2 inducer. They protect different parts of the membrane network and engage different upstream signaling tiers (astaxanthin also activates Nrf2 but more weakly than CA's proelectrophilic flip). Layered membrane antioxidant + Nrf2 redundancy. Co-administer at breakfast with fat.
• NAC (Dylan's V4 Swanson 1200 mg/day): Strongly synergistic. NAC is a glutathione precursor (provides cysteine substrate); CA induces glutathione synthesis (via Nrf2-driven GCLC). NAC supplies the building blocks; CA turns up the factory. The combination drives glutathione pool restoration faster than either alone. No interaction; safe co-administration. Already in V4.
• idebenone (Dylan's V5 contingency, 90-180 mg/day): Mechanistically complementary. Idebenone is a BBB-crossing electron carrier that activates Nrf2 via NQO1; CA is a BBB-crossing proelectrophilic Keap1 modifier. Both end at Nrf2-driven gene induction but enter the pathway at different nodes. Both BBB-cross; both lipid-soluble; both fat-meal absorption. No documented competition.
• cerebrolysin (Dylan's V5 plan, 5 mL IM × 10-20 days q3mo): Mechanistically complementary, not redundant. Cerebrolysin is a neurotrophic peptide cocktail (BDNF/NGF mimetics); CA is the antioxidant gene-induction layer. Cerebrolysin is the regenerative-protection cycle layer; CA is the daily oxidative-protection floor. Particularly useful for Dylan's MMA subconcussive thesis — cerebrolysin supports plasticity and recovery from impact insult, CA reduces the oxidative cascade that determines how badly an impact damages a neuron in the first place.
• omega-3 / DHA (Dylan's V4 Carlson DHA Gems): Provides the lipid vehicle for absorption + the membrane substrate that CA helps protect from peroxidation. DHA is the most peroxidation-susceptible fatty acid in human tissue; CA's Nrf2-driven antioxidant battery directly reduces DHA peroxidation. Co-administer at breakfast.
• vitamin C, vitamin E, alpha-lipoic acid, CoQ10: All members of the broader endogenous antioxidant network that CA upregulates. Layered protection at different membrane zones and aqueous compartments. No documented antagonism.
• sulforaphane (broccoli sprouts, BroccoMax, etc.): Both are Nrf2 activators but via different mechanisms (sulforaphane is a direct electrophile; CA is proelectrophilic). Theoretically additive, although both alone push Nrf2 strongly enough that the marginal benefit of stacking is unclear. No clinical interaction data.
• modafinil, bromantane, Adamax/Semax, ALCAR, taurine, apigenin (Dylan's V5 cognitive layer): No mechanism overlap with CA; no documented interactions; safe co-administration.

Avoid stacking with

• High-dose acetaminophen / chronic heavy alcohol: Hepatotoxicity stacking concern at high CA doses (>300 mg/day). Not Dylan's situation.
• Narrow-therapeutic-index CYP3A4 substrates at very high CA doses (>500 mg/day): cyclosporine, tacrolimus, certain statins, hormonal contraceptives, some antiarrhythmics. Theoretical only at supplement doses; flag for high-dose users.
• Other strong Nrf2 activators at supraphysiological doses combined — sulforaphane + bardoxolone + dimethyl fumarate stacking with high-dose CA could theoretically push Nrf2 too hard (chronic Nrf2 hyperactivation has its own concerns: cancer-cell survival effects, immune dampening). Not relevant at standard doses.

Neutral / safe co-administration

• All V4 stack items: NAC, citicoline, magnesium, phosphatidylserine, rhodiola, theanine, glycine/tryptophan, D3+K2, beta-alanine, creatine, vitamin C.
• All V5 cognitive additions: modafinil, bromantane, Adamax/Semax, taurine, apigenin, astaxanthin, ALCAR.
• BPC-157 / TB-500 healing peptides — different mechanism, no interaction documented.

• CYP3A4: Mild in vitro induction + inhibition (substrate-dependent) at micromolar concentrations. Clinical relevance at 60-180 mg/day supplement doses is likely minimal — no documented drug-level interactions in human studies. Flag for narrow-therapeutic-index CYP3A4 substrates only at high doses (>300 mg/day pure CA).
• CYP2B6: Mild in vitro induction. Minimal clinical relevance at supplement doses.
• CYP2C9: Mild in vitro inhibition. Theoretical interaction with warfarin (CYP2C9 substrate) at high CA doses; not documented clinically.
• Hepatotoxic co-medications: Additive hepatic load — flag if Dylan ever uses high-dose acetaminophen, isotretinoin, methotrexate, or alcohol at CA doses >200-300 mg/day. Not his current situation.
• Anticoagulants / antiplatelets: No documented clinical interaction. Theoretical concern via CYP2C9 (warfarin) at very high doses only.
• Hormonal contraceptives: Theoretical CYP3A4-induction concern at high doses. Not relevant to Dylan; flag for any female user on OCPs.
• Iron supplementation: Phenolic compounds bind iron in the gut and can reduce non-heme iron absorption. Take CA / rosemary extract at least 2 hours apart from iron supplements if iron status is borderline.

This is one of the more interesting pharmacogenomic cases in the supplement space — CA's efficacy depends on the entire Nrf2/Keap1 pathway being intact, and there are several documented polymorphisms that affect that pathway. Dylan's 23andMe results in June 2026 should clarify several of them.

• NFE2L2 promoter polymorphisms (rs6721961 C>A, rs35652124 G>A). Both are in the NRF2 (NFE2L2) gene promoter region and both reduce Nrf2 transcriptional activity (loss-of-function variants).

  • rs6721961: A allele is associated with high oxidative stress, low antioxidant capacity, insulin resistance, increased diabetes/hypertension risk. Caucasian frequency: ~10% AA homozygous, ~35% CA heterozygous, ~55% CC wild-type.
  • rs35652124: A allele linked to lower Nrf2 expression and more severe inflammatory activity in alcoholic liver disease. Frequencies vary by population.
  • Implication for CA response: carriers of the A alleles at either SNP have reduced baseline Nrf2 induction capacity. The proelectrophilic mechanism still works (Keap1 cysteine alkylation is the same), but the downstream Nrf2 transcriptional output is dampened. Likely smaller effect size in heterozygous carriers; potentially poor responders in homozygous A/A carriers.
  • 23andMe v5 chip coverage of these specific SNPs is variable — may need to derive from imputation or order a follow-up panel (e.g., Promethease analysis of raw 23andMe data, or a dedicated Nrf2-pathway panel).
  • Action for Dylan: When 23andMe lands (~June 2026), pull rs6721961 and rs35652124 status. If wild-type at both: CA case strengthens. If heterozygous: still likely a responder, slightly attenuated. If homozygous loss-of-function at either: deprioritize CA, consider stacking with NAC + glutathione + sulforaphane to maximize what Nrf2 capacity remains.

• KEAP1 variants. KEAP1 is the cysteine-rich protein that CA alkylates. Loss-of-function KEAP1 variants (rare, mostly in cancer contexts) would actually enhance baseline Nrf2 activity and reduce the marginal benefit of CA. Gain-of-function KEAP1 variants would dampen Nrf2 activation across all electrophiles including CA. Not commonly genotyped; not on 23andMe v5.

• NQO1 rs1800566 (C609T). Same SNP relevant to idebenone. NQO1 is one of CA's downstream Nrf2 target genes — the T allele (loss-of-function) reduces baseline NQO1 activity, but CA upregulates NQO1 expression so the relative benefit may actually be larger in T-allele carriers (more headroom for induction). Speculative.

• GSTM1 / GSTT1 deletions. Glutathione-S-transferase null genotypes are common (~50% of Caucasians for GSTM1-null) and modestly increase oxidative stress baseline. CA's Nrf2 induction upregulates GST expression, so GST-null carriers may benefit relatively more from CA supplementation. Speculative; no controlled data.

• APOE4 carriers. Speculative — Nrf2 dysfunction is one mechanism in APOE4-driven oxidative stress in AD. CA's mechanism is plausibly more useful in APOE4 carriers, but no human stratified data exists. If Dylan's 23andMe returns APOE4: rationale strengthens marginally.

Bottom line: CA is one of a handful of supplements where 23andMe results have a plausible bearing on response prediction. Pull the NFE2L2 promoter SNPs after 23andMe results land before committing to long-term use. The compound is cheap enough that an empirical 8-12 week trial is also defensible regardless of genotype.

Dylan's recommendation: Doublewood Rosemary Extract 20% CA (500 mg caps), 1-2 caps/day with breakfast = 100-200 mg CA daily, ~$10-15/mo on Amazon. Fits the existing Amazon V4 channel; reliable vendor; convenient encapsulation. Alternative: Pure Bulk 90% CA powder if he wants the cheapest /mg-pure-CA option and is comfortable with powder dosing (~$5-10/mo).

• Baseline (before starting):

  • ALT, AST, GGT — hepatic enzymes (the relevant watch panel at any sustained CA dose).
  • Lipid panel (TC, LDL, HDL, TG) — for tracking the metabolic / anti-adipogenic preclinical signal.
  • hsCRP — inflammation marker; CA's anti-inflammatory mechanism predicts modest decrease.
  • Optional / specialty: MDA (malondialdehyde), oxidized LDL, total antioxidant capacity (TAC), glutathione (reduced + oxidized) — better oxidative-stress proxies; usually only via specialty panels.
  • NFE2L2 rs6721961 + rs35652124 — Nrf2 promoter genotype; pharmacogenomically informative.
  • NQO1 rs1800566 — downstream Nrf2 target; co-relevant with idebenone decisions.
  • APOE genotype — speculative response modifier.
  • Subjective: cognitive-fatigue rating at end of 6-12 hr workday (1-10); post-training muscle soreness rating; digital-eye-strain rating.

• During use (every 6-12 months):

  • ALT/AST/GGT at week 8-12 if dosing >200 mg/day pure CA chronically; otherwise routine semiannual.
  • hsCRP, lipid panel — looking for modest improvements at 12-24 weeks.
  • MDA / oxidized LDL / TAC if specialty panel available — looking for delta after 12 weeks.
  • Subjective ratings (rough delta tracking).

• Post-cycle (if cycled): N/A — no cycling.

For Dylan specifically: tie this into the June 2026 baseline panel. ALT/AST/GGT are already standard liver-panel components. NFE2L2 SNPs derive from 23andMe (verify chip coverage; flag for follow-up imputation panel if needed).